Coverage by the News Media of the Benefits and Risks of Medications

View/ Open
Author
Moynihan, Ray
Bero, Lisa
Henry, David
Lee, Kirby
Watkins, Judy
Mah, Connie
Published Version
https://doi.org/10.1056/NEJM200006013422206Metadata
Show full item recordCitation
Moynihan, Ray, Lisa Bero, Dennis Ross-Degnan, David Henry, Kirby Lee, Judy Watkins, Connie Mah, and Stephen B. Soumerai. 2000. “Coverage by the News Media of the Benefits and Risks of Medications.” New England Journal of Medicine 342 (22) (June): 1645–1650. doi:10.1056/nejm200006013422206.Abstract
Background The news media are an important source of information about new medical treatments, but there is concern that some coverage may be in- accurate and overly enthusiastic.Methods We studied coverage by U.S. news media of the benefits and risks of three medications that are used to prevent major diseases. The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease. We analyzed a systematic probability sample of 180 newspaper articles (60 for each drug) and 27 television reports that ap- peared between 1994 and 1998.
Results Of the 207 stories, 83 (40 percent) did not report benefits quantitatively. Of the 124 that did, 103 (83 percent) reported relative benefits only, 3 (2 per- cent) absolute benefits only, and 18 (15 percent) both absolute and relative benefits. Of the 207 stories, 98 (47 percent) mentioned potential harm to patients, and only 63 (30 percent) mentioned costs. Of the 170 stories citing an expert or a scientific study, 85 (50 percent) cited at least one expert or study with a financial tie to a manufacturer of the drug that had been disclosed in the scientific literature. These ties were disclosed in only 33 (39 percent) of the 85 stories.
Conclusions News-media stories about medications may include inadequate or incomplete information about the benefits, risks, and costs of the drugs as well as the financial ties between study groups or experts and pharmaceutical manufacturers.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:32691994
Collections
- HMS Scholarly Articles [17714]
Contact administrator regarding this item (to report mistakes or request changes)